Smartleaf Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Smartleaf Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-575	Closed	-$10.6K	–	3489
2026 Q1	$10.6K	Hold	575	–	–	﹤0.01%	2300
2025 Q4	$9.02K	Buy	575 +322	+127%	+$4.26K	﹤0.01%	2439
2025 Q3	$3.09K	Buy	+253	New	+$3.5K	﹤0.01%	2502
2025 Q2	–	Sell	-279	Closed	-$3.33K	–	2865
2025 Q1	$3.33K	Sell	279 -27	-9%	-$276	﹤0.01%	2333
2024 Q4	$2.57K	Hold	306	–	–	﹤0.01%	2462
2024 Q3	$3.78K	Buy	306 +227	+287%	+$2.85K	﹤0.01%	2246
2024 Q2	$951	Buy	+79	New	+$922	﹤0.01%	2432

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Smartleaf Asset Management's KALV Position: Q2 2026 in Review

Smartleaf Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 575 shares — an estimated $10.6K sold.

Smartleaf Asset Management first reported a position in KALV in Q2 2024 and held it in 7 quarters. The position peaked at $10.6K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Smartleaf Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Smartleaf Asset Management sold 575 KalVista Pharmaceuticals shares in Q2 2026, an estimated $10.6K.
Smartleaf Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2024 and held it in 7 quarters.
Smartleaf Asset Management's KalVista Pharmaceuticals position peaked at $10.6K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.